Physician profile
Karan Omidvari
NPI 1962474742
$4,067.47
in general payments reported to CMS, 2019-2025
36 companies · $2,973 in 2025
The $2,973 reported for 2025 was more than what 90% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $61.35 · 2021: $213 · 2022: $328 · 2023: $176 · 2024: $316 · 2025: $2,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212 · Education: $193 · Consulting Fee: $61.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.83 |
| Education | $192.88 |
| Consulting Fee | $61.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,133.11 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $488.00 | 2020-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Insmed, INC. | $238.79 | 2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $229.74 | 2025 | |
| Amgen INC. | $222.58 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $205.30 | 2025 | Yupelri |
| United Therapeutics Corporation | $144.77 | 2021-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $144.49 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $135.45 | 2025 | Uptravi, Opsumit, Opsynvi |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Intuitive Surgical, INC. | $89.18 | 2024 | |
| Merck Sharp & Dohme LLC | $87.41 | 2020-2025 | Recarbrio, Zerbaxa, Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.39 | 2020-2025 | Jascayd |
| Grifols USA, LLC | $70.61 | 2022-2025 | Prolastin-C Liquid |
| Adma Biomanufacturing LLC | $61.11 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $55.04 | 2020-2023 | |
| Inquis Medical, INC. | $54.55 | 2024 | |
| Harmony Biosciences LLC | $53.41 | 2025 | |
| Mallinckrodt Hospital Products INC. | $50.80 | 2021-2025 | Acthar |
| Mindray Ds USA, INC. | $47.49 | 2024 | Te7 Max, Te X |
| Abiomed | $40.61 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $35.78 | 2025 | Dupixent |
| Pfizer INC. | $32.00 | 2021-2022 | |
| Mylan Specialty L.P. | $31.77 | 2022-2024 | Yupelri |
| Abbvie INC. | $30.87 | 2022-2023 | |
| Medtronic, INC. | $26.19 | 2021 | |
| Baxter Healthcare | $23.48 | 2022 | |
| Advanced Respiratory, INC | $22.65 | 2021 | |
| Electromed, INC. | $20.13 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.86 | 2024 | Glassia |
| Ani Pharmaceuticals, INC. | $15.93 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $15.45 | 2025 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.01 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $14.62 | 2025 | Lumryz |
| Nestle Healthcare Nutrition INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Omidvari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.